Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183330 | 0.87 | HMGCR (0.41) | HMGCRPTPN1TBXAS1 | |
| SCHEMBL13183289 | 0.86 | HMGCR (0.43) | HMGCRPTPN1TBXAS1 | |
| SCHEMBL13183306 | 0.86 | HMGCR (0.43) | HMGCRPTPN1TBXAS1 | |
| SCHEMBL4245009 | 0.83 | FAAH (0.50) | FAAHCNR2PTPN1TBXAS1 | |
| SCHEMBL13183245 | 0.82 | PTPN1 (0.38) | HMGCRPTPN1TBXAS1 | |
| SCHEMBL4238610 | 0.81 | PTPN1 (0.38) | HMGCRPTPN7PTPN1PPARDTBXAS1 | |
| SCHEMBL4239587 | 0.81 | PTPN1 (0.38) | HMGCRPTPN7PTPN1PPARDTBXAS1 | |
| SCHEMBL4932579 | 0.81 | PTPN1 (0.38) | HMGCRPTPN7PTPN1PPARDTBXAS1 | |
| SCHEMBL268519 | 0.77 | HMGCR (0.69) | HMGCRPTPN7PTPN1 | |
| SCHEMBL3510230 | 0.77 | HMGCR (0.69) | HMGCRPTPN7PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | LIPE, PNLIP, FAAH2 | HMGCR 1770/4885PTPN7 3289/4885FAAH 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.